SCHEMBL1102997

SCHEMBL1102997

c1ccc2c(-c3cc(-c4ccncc4)nc(-c4ccncc4)n3)c3ncccc3c(-c3cc(-c4ccncc4)nc(-c4ccncc4)n3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
PRKCH P24723 2/20 0.40
PRKCE Q02156 2/20 0.40
KDM4E B2RXH2 5/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
DHODH Q02127 1/20 0.38
CYP19A1 P11511 1/20 0.38
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102947 0.91 TOP1 (0.49) TOP1KDM4EL3MBTL1NPC1MEN1
SCHEMBL23996431 0.85 MEN1 (0.51) CYP3A4CYP2C9KDM4EMEN1KMT2A
SCHEMBL18623355 0.81 MEN1 (0.51) CYP3A4CYP2C9KDM4EMEN1KMT2A
SCHEMBL1102543 0.81 LATS1 (0.43) CYP3A4CYP2C9PRKCHPRKCEKDM4E
SCHEMBL18623326 0.77 MEN1 (0.54) CYP3A4CYP2C9KDM4EMEN1KMT2A
SCHEMBL1103338 0.77 PDGFRB (0.42) CYP3A4CYP2C9KDM4ENPC1RAB9A
SCHEMBL1102887 0.76 MAPK14 (0.45) CYP3A4CYP2C9KDM4EL3MBTL1NPC1
SCHEMBL13649230 0.76 MEN1 (0.60) KDM4EL3MBTL1MEN1KMT2AMAPT
SCHEMBL21308710 0.75 TOP1 (0.51) TOP1CYP3A4KDM4EL3MBTL1NPC1
SCHEMBL1102755 0.75 MEN1 (0.47) CYP3A4CYP2C9KDM4EL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 TOP1 4307/4885CYP3A4 1409/4885CYP2C9 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.